Tofacitinib in Children with Ulcerative Colitis (Pfizer OVATION Protocol A3921210)
To evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active Ulcerative Colitis (UC).
To evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active Ulcerative Colitis (UC).
The primary aim of this registry will be to identify genes and/or biologic and environmental factors that either cause these tumors or increase one's risk for developing them. Ultimately, research using this registry may result in improved diagnosis, more effective treatments and possibly prevention.
CD19 is a B-cell surface protein expressed throughout B cell development; therefore, it is expressed on nearly all B cell malignancies, including acute lymphoblastic leukemia (ALL),and many non-Hodgkin lymphomas. B cell neoplasms are clonal tumors of mature and immature B lymphocytes (e.g., acute lymphoblastic leukemia).UCART19 is intended to treat CD19-positive B lymphoid malignancies in paediatric and adult populations.